SN50 |
| カタログ番号GC31642 |
SN50はNF-κB細胞透過性阻害ペプチドである。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 213546-53-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SN50はNF-κB細胞透過性阻害ペプチドである。膜移行モチーフとしてのカポジ繊維芽細胞増殖因子のシグナルペプチドの親水性領域と NF-κBのp50サブユニットからの核局在配列から構成される[１]。
SN50(20μg/ml;12h)はNF-κB経路でミクログリアのM2型への分化を誘発できる。SN50が誘発したミクログリアはニューロンを酸素不足損傷から保護できる[2]。 SN50（25 µg/ml；24 h）はGSCの強烈な分化を誘発でき、分化した子細胞は腫瘍細胞幹細胞の神経球運動性、浸潤性、治療の否感受性の腫瘍形成性を失う[4]。
SN50(100μl,10,30,60μg/ml; i.p.;1h)はNF-κB p65の転座 を阻害することでARDSにおける肺胞凝固亢進および線溶の阻害を軽減する[5]。SN50(1μM)は隔離されたラットにおけるLPSが誘発した肺損傷から保護され、NF-κBの転座を阻害することで肺機能を改善する[6]。
局所でSN50（10μM；12日間）は細胞の核因子-κBの活性化を阻害し、角膜治癒の C57BL/6鼠における上皮欠損/潰瘍形成の発生率を減少させる[7]。
References:
[1]. Lin YZ, Yao SY,et al. Inhibition of nuclear translocation of transcription factor NF kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 1995;270(24):14255-8.
[2]. Chian CF, Chiang CH, et,al. Inhibitor of nuclear factor-κB, SN50, attenuates lipopolysaccharide-induced lung injury in an isolated and perfused rat lung model. Transl Res. 2014 Mar;163(3):211-20. doi: 10.1016/j.trsl.2013.10.002. Epub 2013 Oct 12. PMID: 24646628.
[3]. Zhang L, Ren X, et,al. The NFκB inhibitor, SN50, induces differentiation of glioma stem cells and suppresses their oncogenic phenotype. Cancer Biol Ther. 2014 May;15(5):602-11. doi: 10.4161/cbt.28158. Epub 2014 Feb 20. PMID: 24557012; PMCID: PMC4026083.
[4]. Zhao K, Zhu BS, et,al. SN50 enhances the effects of LY294002 on cell death induction in gastric cancer cell line SGC7901. Arch Med Sci. 2013 Dec 30;9(6):990-8. doi: 10.5114/aoms.2013.39790. Epub 2013 Dec 26. PMID: 24482641; PMCID: PMC3902720.
[5]. Wu Y, Wang Y, et,al.SN50 attenuates alveolar hypercoagulation and fibrinolysis inhibition in acute respiratory distress syndrome mice through inhibiting NF-κB p65 translocation. Respir Res. 2020 May 27;21(1):130. doi: 10.1186/s12931-020-01372-6. PMID: 32460750; PMCID: PMC7251840.
[6]. Chian CF, Chiang CH, et,al. Inhibitor of nuclear factor-κB, SN50, attenuates lipopolysaccharide-induced lung injury in an isolated and perfused rat lung model. Transl Res. 2014 Mar;163(3):211-20. doi: 10.1016/j.trsl.2013.10.002. Epub 2013 Oct 12. PMID: 24646628.
[7]. Saika S, Miyamoto T, et,al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice. Am J Pathol. 2005 May;166(5):1393-403. doi: 10.1016/s0002-9440(10)62357-7. PMID: 15855640; PMCID: PMC1606394.
| 細胞実験[１]: | |
細胞株 | 神経膠腫幹細胞様細胞GSC11 と GSC23 細胞 |
準備方法 | 2% B-27、20 ng/mL EGF と20 ng/mL β-FGFが含んでいる培地で存在するまたは存在しないSN50 (25 µg/mL) の条件で２４時間培養する |
反応条件 | 25 µg/mL； 24時間 |
アプリケーション | SN50はGSCの分化を誘発できる。 |
| 動物実験 [２]: | |
動物モデル | オスBalb/c鼠（8-12週間） |
準備方法 | 鼠に 50 µlのリポ多糖類(LPS) (4 mg/ml)を吸入させる。鼠に吸入させた1時間前に異なる用量のSN50を腹腔内注射させる。 |
投与形態 | 100μl、10、30、60μg/ml；i.p；1時間 |
アプリケーション | SN50はLPSが誘発した急性呼吸窮迫症候群 (ARDS)の鼠におけるmRNAとタンパク質の発現レベルを阻害する。 |
References: | |
| Cas No. | 213546-53-3 | SDF | |
| Canonical SMILES | Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro | ||
| Formula | C129H230N36O29S | M.Wt | 2781.5 |
| 溶解度 | Water : ≥ 50 mg/mL (17.98 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3595 mL | 1.7976 mL | 3.5952 mL |
| 5 mM | 0.0719 mL | 0.3595 mL | 0.719 mL |
| 10 mM | 0.036 mL | 0.1798 mL | 0.3595 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 19 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *